Second-Trimester Inflammatory Markers in Predicting Fetal Growth Restriction: A Retrospective Analysis

IF 2.5 3区医学 Q3 IMMUNOLOGY

American Journal of Reproductive Immunology Pub Date : 2025-01-17 DOI:10.1111/aji.70047

Gizem Aktemur, Betül Tokgöz Çakır, Gülşan Karabay, Ahmet Arif Filiz, Zeynep Seyhanlı, Serap Topkara Sucu, Nazan Vanlı Tonyalı, Şevki Çelen

{"title":"Second-Trimester Inflammatory Markers in Predicting Fetal Growth Restriction: A Retrospective Analysis","authors":"Gizem Aktemur, Betül Tokgöz Çakır, Gülşan Karabay, Ahmet Arif Filiz, Zeynep Seyhanlı, Serap Topkara Sucu, Nazan Vanlı Tonyalı, Şevki Çelen","doi":"10.1111/aji.70047","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Problem:</h3>\n \n <p>Fetal growth restriction (FGR) is a critical pregnancy complication linked to increased perinatal morbidity and mortality. Inflammation plays a key role in FGR's pathophysiology, and systemic inflammation markers may serve as predictors. This study evaluates the role of various inflammation indices; systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-platelet ratio (LMR), monocyte-to-platelet ratio (MPR), aggregate systemic inflammation index (AISI), systemic coagulation inflammation index (SCII), and immature granulocyte percentage (IG%) in predicting FGR.</p>\n </section>\n \n <section>\n \n <h3> Methods of Study</h3>\n \n <p>This retrospective study included 403 pregnant women treated at Ankara Etlik City Hospital between August 2022 and May 2024. The study population comprised 202 women with uncomplicated pregnancies (control group) and 201 women diagnosed with FGR per the Delphi Consensus Criteria. Second-trimester blood samples were used to calculate the inflammatory indices.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>SII and NLR levels were significantly higher in the FGR group compared to controls (<i>p</i> = 0.020, <i>p</i> = 0.028, respectively). However, no significant associations were found between these indices and adverse neonatal outcomes. Cut-off values for SII and NLR were 896 and 3.91, respectively, with moderate sensitivity and specificity.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SII and NLR, measured in the second trimester, may be useful in predicting FGR. Although these indices did not correlate with adverse neonatal outcomes, further prospective studies with larger populations are needed to validate their clinical utility.</p>\n </section>\n </div>","PeriodicalId":7665,"journal":{"name":"American Journal of Reproductive Immunology","volume":"93 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Reproductive Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aji.70047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Problem:

Fetal growth restriction (FGR) is a critical pregnancy complication linked to increased perinatal morbidity and mortality. Inflammation plays a key role in FGR's pathophysiology, and systemic inflammation markers may serve as predictors. This study evaluates the role of various inflammation indices; systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-platelet ratio (LMR), monocyte-to-platelet ratio (MPR), aggregate systemic inflammation index (AISI), systemic coagulation inflammation index (SCII), and immature granulocyte percentage (IG%) in predicting FGR.

Methods of Study

This retrospective study included 403 pregnant women treated at Ankara Etlik City Hospital between August 2022 and May 2024. The study population comprised 202 women with uncomplicated pregnancies (control group) and 201 women diagnosed with FGR per the Delphi Consensus Criteria. Second-trimester blood samples were used to calculate the inflammatory indices.

Results

SII and NLR levels were significantly higher in the FGR group compared to controls (p = 0.020, p = 0.028, respectively). However, no significant associations were found between these indices and adverse neonatal outcomes. Cut-off values for SII and NLR were 896 and 3.91, respectively, with moderate sensitivity and specificity.

Conclusions

SII and NLR, measured in the second trimester, may be useful in predicting FGR. Although these indices did not correlate with adverse neonatal outcomes, further prospective studies with larger populations are needed to validate their clinical utility.

查看原文本刊更多论文

妊娠中期炎症标志物预测胎儿生长受限：回顾性分析。

问题：胎儿生长受限（FGR）是一种与围产期发病率和死亡率增加相关的重要妊娠并发症。炎症在FGR的病理生理中起关键作用，全身性炎症标志物可作为预测因子。本研究评价各种炎症指标的作用；全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）、泛免疫炎症值（PIV）、中性粒细胞与淋巴细胞比率（NLR）、血小板与淋巴细胞比率（PLR）、单核细胞与淋巴细胞比率（MLR）、淋巴细胞与血小板比率（LMR）、单核细胞与血小板比率（MPR）、全身炎症指数（AISI）、全身凝血炎症指数（SCII）和未成熟粒细胞百分比（IG%）预测FGR。研究方法：这项回顾性研究纳入了2022年8月至2024年5月期间在安卡拉埃特利克市医院接受治疗的403名孕妇。研究人群包括202名无并发症妊娠妇女（对照组）和201名根据德尔菲共识标准诊断为FGR的妇女。采用妊娠中期血样计算炎症指数。结果：FGR组SII和NLR水平明显高于对照组（p = 0.020, p = 0.028）。然而，在这些指标和新生儿不良结局之间没有发现显著的关联。SII和NLR的临界值分别为896和3.91，具有中等的敏感性和特异性。结论：在妊娠中期测量SII和NLR可能有助于预测FGR。虽然这些指标与不良新生儿结局无关，但需要进一步的前瞻性研究来验证其临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Reproductive Immunology 医学-免疫学

CiteScore

6.20

自引率

5.60%

发文量

314

审稿时长

2 months

期刊介绍： The American Journal of Reproductive Immunology is an international journal devoted to the presentation of current information in all areas relating to Reproductive Immunology. The journal is directed toward both the basic scientist and the clinician, covering the whole process of reproduction as affected by immunological processes. The journal covers a variety of subspecialty topics, including fertility immunology, pregnancy immunology, immunogenetics, mucosal immunology, immunocontraception, endometriosis, abortion, tumor immunology of the reproductive tract, autoantibodies, infectious disease of the reproductive tract, and technical news.